The Food and Drug Administration has reversed its decision on Moderna's flu vaccine and has agreed to review it for possible approval, Moderna announced on Wednesday. From a report: Last week, the agency rejected Moderna's application for review of a new flu vaccine, saying the company's research design was flawed. But in subsequent discussions the company said that the agency had relented and agreed to begin a review. Moderna said it split its application for the flu vaccine based on age, seeking a traditional approval for people 50 to 64 years old, and accelerated approval for those 65 and older. The company also said it agreed to conduct an additional study among those 65 and older once the vaccine reached the market. Moderna said on Wednesday that the F.D.A. set a deadline of August to decide whether to approve the vaccine. If it is authorized, it would be available for those older adults in the flu season that begins later this year. The vaccine uses messenger RNA technology, which Health Secretary Robert F. Kennedy Jr. has repeatedly criticized as unsafe and ineffective. The mRNA approach, which instructs the body to produce a fragment of a virus that sets off an immune response, was widely successful in Covid vaccines and is considered generally safe by public health experts and scientists.

Read more of this story at Slashdot.

In a small double-blind clinical trial, a single intravenous dose of DMT produced rapid and clinically meaningful reductions in symptoms of major depressive disorder within a week, with effects lasting up to three months in some patients. "Unlike psilocybin and lysergic acid diethylamide ( LSD), whose effects can last for hours, intravenous DMT has a half-life of around five minutes," notes ScienceAlert. "Its psychedelic effects are correspondingly brief, potentially making it more practical to administer in clinical settings." From the report: "A single dose of DMT with psychotherapeutic support produced a rapid, significant reduction in depressive symptoms, sustained up to three months," writes a team led by neuroscientists David Erritzoe and Tommaso Barba of Imperial College London. [...] They recruited 34 participants with major depression and divided them into two groups of 17 for a double-blind, placebo-controlled trial. In the first stage of the trial, one group received an intravenous dose of DMT, while the other received an active placebo. Neither the researchers nor the participants were informed which participants received the DMT. The doses took around 10 minutes to administer, and a therapist sat with each participant to ensure comfort and safety while the psychedelic effects were active, remaining silent throughout the treatment. The treatment was generally well tolerated. Most side effects were mild to moderate, and included nausea, temporary anxiety, and pain at the injection site. No serious adverse events related to the treatment were reported, although brief increases in heart rate and blood pressure were observed immediately after dosing. In the second, open-label stage, two weeks after the first dose, all participants were given the opportunity to receive a dose of DMT. Participants were assessed before and at intervals after each dose using the Montgomery-Asberg Depression Rating Scale. Just a week after the first dose, participants who had received DMT had improved scores compared to the placebo group, and improvements were sustained during follow-up assessments. Two weeks after the first dose, the participants who received DMT scored about seven points lower, on average, than those who received a placebo. On this commonly used clinical scale, a drop of that size is generally considered a meaningful reduction in symptom severity. There was no significant difference between patients who received one or two doses of DMT, suggesting a single dose may be sufficient. These effects persisted for up to three months, and some patients remained in remission for at least six months following the treatment. The findings have been published in Nature Medicine.

Read more of this story at Slashdot.

Longtime Slashdot reader walterbyrd shares a report from ABC News: In a study of nearly 28 million older Americans, long-term exposure to fine particle air pollution raised the risk of Alzheimer's disease. That link held even after researchers accounted for common conditions like high blood pressure, stroke and depression. Fine particle air pollution, known as PM2.5, consists of tiny particles in the air that come from car exhaust, power plants, wildfires, and burning fuels, according to the American Lung Association. They are small enough to travel deep into the lungs and even reach the bloodstream. The research, conducted at Emory University and published in PLOS Medicine, tracked health data over nearly two decades to explore whether air pollution harms the brain indirectly by causing high blood pressure or heart disease, which, in turn, leads to dementia. However, these "middleman" conditions accounted for less than 5% of the connection between pollution and Alzheimer's, the research found. The researchers say this suggests that over 95% of the Alzheimer's risk comes from the direct impact of breathing in dirty air, likely through inflammation or damage to brain cells. "The relationship between PM2.5 and AD [Alzheimer's disease] has been shown to be pretty much linear," said Kyle Steenland, a professor in the departments of environmental health and epidemiology at the Rollins School of Public Health at Emory University, and senior author of the study. "The reason this is particularly important is that PM2.5 is known to be associated with high blood pressure, stroke and depression -- all of which are associated with AD. So, from a prevention standpoint, simply treating these diseases will not get rid of the problem. We have to address exposure to PM2.5."

Read more of this story at Slashdot.

Up to a third of people worldwide have shoulder pain; it's one of the most common musculoskeletal complaints. But medical imaging might not reveal the problem -- in fact, it could even cloud it. From a report: In a study published in JAMA Internal Medicine this week, 99 percent of adults over 40 were found to have at least one abnormality in a rotator cuff on magnetic resonance imaging (MRI). The rotator cuff is the group of muscles and tendons in a shoulder joint that keeps the upper arm bone securely in the shoulder socket -- and is often blamed for pain and other symptoms. The trouble is, the vast majority of the people in the study had no problems with their shoulders. The finding calls into question the growing use of MRIs to try to diagnose shoulder pain -- and, in turn, the growing problem of overtreatment of rotator cuff (RC) abnormalities, which includes partial- and full-thickness tears as well as signs of tendinopathy (tendon swelling and thickening). "While we cannot dismiss the possibility that some RC tears may contribute to shoulder symptoms, our findings indicate that we are currently unable to distinguish clinically meaningful MRI abnormalities from incidental findings," the study authors concluded.

Read more of this story at Slashdot.

"Research published in the World Journal of Men's Health found evidence that drugs such as Viagra and Cialis may also help with heart disease, stroke risk and diabetes," reports the Telegraph, "as well as enlarged prostate and urinary problems." Researchers found evidence that the same mechanism may benefit other organs, including the heart, brain, lungs and urinary system. The paper reviewed a wide range of published studies [and] identified links between PDE5 inhibitor use and improvements in cardiovascular health. Heart conditions were repeatedly cited as an area where improved blood flow and muscle relaxation may offer benefits. Evidence also linked PDE5 inhibitors with reduced stroke risk, likely to be related to improved circulation and vascular function. Diabetes was another condition where associations with improvement were identified... The review also found evidence of benefit for men with an enlarged prostate, a condition that commonly causes urinary symptoms.

Read more of this story at Slashdot.

An anonymous reader shares a report: The Food and Drug Administration has refused to start a review of Moderna's application for its experimental flu shot, the company announced Tuesday, in another sign of the Trump administration's influence on tightening vaccine regulations in the U.S. Moderna said the move is inconsistent with previous feedback from the agency from before it submitted the application and started phase three trials on the shot, called mRNA-1010. The drugmaker said it has requested a meeting with the FDA to "understand the path forward." Moderna noted that the agency did not identify any specific safety or efficacy issues with the vaccine, but instead objected to the study design, despite previously approving it. The company added that the move won't impact its 2026 financial guidance. Moderna's jab showed positive phase three data last year, meeting all of the trial goals. At the time, Moderna said the stand-alone flu shot was key to its efforts to advance a combination vaccine targeting both influenza and Covid-19.

Read more of this story at Slashdot.

As Super Bowl Sunday comes to a close, America's National Football League "is challenging innovators to improve the facemask on football helmets to reduce concussions in the game," reports the Associated Press: The league announced on Friday at an innovation summit for the Super Bowl the next round in the HealthTECH Challenge series, a crowdsourced competition designed to accelerate the development of cutting-edge football helmets and new standards for player safety. The challenge invites inventors, engineers, startups, academic teams and established companies to improve the impact protection and design of football helmets through improvements to how facemasks absorb and reduce the effects of contact on the field... Most progress on helmet safety has come from improvements to the shell and padding, helping to reduce the overall rate of concussions. Working with the helmet industry, the league has brought in position-specific helmets, with those for quarterbacks, for example, having more padding in the back after data showed most concussions for QBs came when the back of the head slammed to the turf. But the facemask has mostly remained the same. This past season, 44% of in-game concussions resulted from impact to the player's facemask, up from 29% in 2015, according to data gathered by the NFL. "What we haven't seen over that period of time are any changes of any note to the facemask," [said Jeff Miller, the NFL's executive vice president overseeing player health and safety]... "Now we see, given the changes in our concussion numbers and injuries to players, that as changes are made to the helmet, fewer and fewer concussions are caused by hits to the shell, and more and more concussions as a percentage are by hits to the facemask..." Selected winners will receive up to $100,000 in aggregate funding, as well as expert development support to help move their concepts from the lab to the playing field. Winners will be announced in August, according to the article, "and Miller said he expected helmet manufacturers to start implementing any improvements into helmets soon after that."

Read more of this story at Slashdot.

"After a half-century asking us to exercise more, doctors and physiologists say we have been thinking about it wrong," writes Washington Post columnist Michael J. Coren. "U.S. and World Health Organization guidelines no longer specify a minimum duration of moderate or vigorous aerobic activity." Movement-tracking studies show even tiny, regular bursts of effort — as short as 30 seconds — can capture many of the health benefits of the gym. Climbing two to three flights of stairs a few times per day could change your life. Experts call it VILPA, or vigorous intermittent lifestyle physical activity. "The message now is that all activity counts," said Martin Gibala, a professor and former chair of the kinesiology department at McMaster University in Canada... Just taking the stairs daily is associated with lower body weight and cutting the risk of stroke and heart disease — the leading (and largely preventable) cause of death globally. While it may not burn many calories (most exercise doesn't), it does appear to extend your health span. Leg power — a measure of explosive muscle strength — was a stronger predictor of brain aging than any lifestyle factors measured in a 2015 study in the journal Gerontology... How little activity can you do? Four minutes daily. Essentially, a few flights of stairs at a vigorous pace. That's the effort [Emmanuel Stamatakis, a professor of physical activity and population health at the University of Sydney] found delivered significant health benefits in that 2022 study of British non-exercisers. "We saw benefits from the first minute," Stamatakis said. For Americans, the effect is even more dramatic: a 44 percent drop in deaths, according to a peer-reviewed paper recently accepted for publication. "We showed for the first time that vigorous intensity, even if it's done as part of the day-to-day routine, not in a planned and structured manner, works miracles," Stamatakis said. "The key principle here is start with one, two minutes a day. The focus should be on making sure that it's something that you can incorporate into your daily routine. Then you can start thinking about increasing the dose." Intensity is the most important factor. You won't break a sweat in a brief burst, but you do need to feel it. A highly conditioned athlete might need to sprint to reach vigorous territory. But many people need only to take the stairs. Use your breathing as a guide, Stamatakis said: If you can sing, it's light intensity. If you can speak but not sing, you're entering moderate exertion. If you can't hold a conversation, it's vigorous. The biggest benefits come from moderate to vigorous movement. One minute of incidental vigorous activity prevents premature deaths, heart attacks or strokes as well as about three minutes of moderate activity or 35 to 49 minutes of light activity.

Read more of this story at Slashdot.

An anonymous reader quotes a report from Wired: About a decade ago, many media outlets -- including WIRED -- zeroed in on a weird trend at the intersection of mental health, drug science, and Silicon Valley biohacking: microdosing, or the practice of taking a small amount of a psychedelic drug seeking not full-blown hallucinatory revels but gentler, more stable effects. Typically using psilocybin mushrooms or LSD, the archetypal microdoser sought less melting walls and open-eye kaleidoscopic visuals than boosts in mood and energy, like a gentle spring breeze blowing through the mind. Anecdotal reports pitched microdosing as a kind of psychedelic Swiss Army knife, providing everything from increased focus to a spiked libido and (perhaps most promisingly) lowered reported levels of depression. It was a miracle for many. Others remained wary. Could 5 percent of a dose of acid really do all that? A new, wide-ranging study by an Australian biopharma company suggests that microdosing's benefits may indeed be drastically overstated -- at least when it comes to addressing symptoms of clinical depression. A Phase 2B trial of 89 adult patients conducted by Melbourne-based MindBio Therapeutics, investigating the effects of microdosing LSD in the treatment of major depressive disorder, found that the psychedelic was actually outperformed by a placebo. Across an eight-week period, symptoms were gauged using the Montgomery-Asberg Depression Rating Scale (MADRS), a widely recognized tool for the clinical evaluation of depression. The study has not yet been published. But MindBio's CEO Justin Hanka recently released the top-line results on his LinkedIn, eager to show that his company was "in front of the curve in microdosing research." He called it "the most vigorous placebo controlled trial ever performed in microdosing." It found that patients dosed with a small amount of LSD (ranging from 4 to 20g, or micrograms, well below the threshold of a mind-blowing hallucinogenic dose) showed observable upticks in feelings of well-being, but worse MADRS scores, compared to patients given a placebo in the form of a caffeine pill. (Because patients in psychedelic trials typically expect some kind of mind-altering effect, studies are often blinded using so-called "active placebos," like caffeine or methylphenidate, which have their own observable psychoactive properties.) This means, essentially, that a medium-strength cup of coffee may prove more beneficial in treating major depressive disorder than a tiny dose of acid. Good news for habitual caffeine users, perhaps, but less so for researchers (and biopharma startups) counting on the efficacy of psychedelic microdosing. "It's probably a nail in the coffin of using microdosing to treat clinical depression," Hanka says. "It probably improves the way depressed people feel -- just not enough to be clinically significant or statistically meaningful."

Read more of this story at Slashdot.

A large Swedish study of 100,000 women found that using AI to assist radiologists reading mammograms reduced the rate of aggressive "interval" breast cancers by 12%. CBC News reports: For the study -- published in Thursday's issue of the medical journal The Lancet -- more than 100,000 women had mammography screenings. Half were supported by AI and the rest had their mammograms reviewed by two different radiologists, a standard practice in much of Europe known as double reading. It is not typically used in Canada, where usually one radiologist checks mammograms. The study looked at the rates of interval cancer, the term doctors use for invasive tumors that appear between routine mammograms. They can be harder to detect and studies have shown that they are more likely to be aggressive with a poorer prognosis. The rate of interval cancers decreased by 12 percent in the groups where the AI screening was implemented, the study showed. [...] Throughout the two-year study, the mammograms that were supported by AI were triaged into two different groups. Those that were determined to be low risk needed only one radiologist to examine them, while those that were considered high risk required two. The researchers reported that numerically, the AI-supported screening resulted in 11 fewer interval cancers than standard screening (82 versus 93, or 12 per cent). "This is really a way to improve an overall screening test," [said lead author, Dr. Kristina Lang]. She acknowledged that while the study found a decrease in interval cancer, longer-term studies are needed to find out how AI-supported screening might impact mortality rates. The screenings for the study all took place at one centre in Sweden, which the researchers acknowledged is a limitation. Another is that the race and ethnicity of the participants were not recorded. The next step, Lang said, will be for Swedish researchers to determine cost-effectiveness.

Read more of this story at Slashdot.

For decades, researchers have noted that cancer and Alzheimer's disease are rarely found in the same person, fuelling speculation that one condition might offer some degree of protection from the other. Nature: Now, a study in mice provides a possible molecular solution to the medical mystery: a protein produced by cancer cells seems to infiltrate the brain, where it helps to break apart clumps of misfolded proteins that are often associated with Alzheimer's disease. The study, which was 15 years in the making, was published on 22 January in Cell and could help researchers to design drugs to treat Alzheimer's disease. "They have a piece of the puzzle," says Donald Weaver, a neurologist and chemist at the Krembil Research Institute at the University of Toronto in Canada, who was not involved in the study. "It's not the full picture by any stretch of the imagination. But it's an interesting piece." [...] A 2020 meta-analysis of data from more than 9.6 million people found that cancer diagnosis was associated with an 11% decreased incidence of Alzheimer's disease. It has been a difficult relationship to unpick: researchers must control for a variety of external factors. For example, people might die of cancer before they are old enough to develop symptoms of Alzheimer's disease, and some cancer treatments can cause cognitive difficulties, which could obscure an Alzheimer's diagnosis.

Read more of this story at Slashdot.

A clinical trial found that seniors at high stroke risk who wore an Apple Watch were four times more likely to have hidden heart rhythm disorders detected than those receiving standard care. The researchers noted that over half the time, these smartwatch wearers with heart rhythm problems hadn't shown any symptoms prior to diagnosis. From U.S. News & World Report: Later editions of Apple Watches are equipped with two functions that can help monitor heart health -- photoplethysmography (PPG), which tracks heart rate, and a single-lead electrocardiogram (ECG) that monitors heart rhythm. "Using smartwatches with PPG and ECG functions aids doctors in diagnosing individuals unaware of their arrhythmia, thereby expediting the diagnostic process," said senior researcher Dr. Michiel Winter, a cardiologist at Amsterdam University Medical Center in The Netherlands. "Our findings suggest a potential reduction in the risk of stroke, benefiting both patients and the health care system by reducing costs," Winter said in a news release. [...] Smartwatches are much easier than other wearable devices for detecting irregular heart rhythms [...]. These other means require people to wear sticky leads, carry around bulky monitors or even receive short-term implants. Lead researcher Nicole van Steijn, a doctoral candidate at Amsterdam UMC, noted that wearables that track both the pulse and electrical activity have been around for a while. "However, how well this technology works for the screening of patients at elevated risk for atrial fibrillation had not yet been investigated in a real-world setting,"she said in a news release. The findings have been published in the Journal of the American College of Cardiology.

Read more of this story at Slashdot.

The United States formally withdrew from the World Health Organization on Thursday, making good on an executive order that President Trump issued on his first day in office pledging to leave the international organization that coordinates global responses to public health threats. The New York Times: While the United States is walking away from the organization, a senior official with the Department of Health and Human Services told reporters on Thursday that the Trump administration was considering some type of narrow, limited engagement with W.H.O. global networks that track infectious diseases, including influenza. As a W.H.O. member, the United States long sent scientists from the Centers for Disease Control and Prevention to participate in international decision-making about which strains to include in the flu vaccine. A W.H.O. meeting on next year's vaccine is scheduled for February. The official said the Trump administration would soon disclose how or whether it will participate. On Thursday, the administration said that all U.S. government funding to the organization had been terminated, and that all assigned federal employees and contractors had been recalled from its Geneva headquarters and its offices worldwide.

Read more of this story at Slashdot.

alternative_right shares a report from ScienceAlert: A systematic review of 85 studies has now found good reason to differentiate between 'active' sitting, like playing cards or reading, and 'passive' sitting, like watching TV. [...] "Total sitting time has been shown to be related to brain health; however, sitting is often treated as a single entity, without considering the specific type of activity," explains public health researcher Paul Gardiner from the University of Queensland in Australia. "Most people spend many hours sitting each day, so the type of sitting really matters ... These findings show that small everyday choices -- like reading instead of watching television -- may help keep your brain healthier as you age." Across numerous studies, Gardiner and colleagues found that active sitting activities, like reading, playing card games, and using a computer, showed "overwhelmingly positive associations with cognitive health, enhancing cognitive functions such as executive function, situational memory, and working memory." Meanwhile, passive sitting was most consistently associated with negative cognitive outcomes, including increased risk of dementia. The study was published in the Journal of Alzheimer's Disease.

Read more of this story at Slashdot.

An anonymous reader shares a report: Moderna does not plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from U.S. officials, CEO Stephane Bancel said in an interview with Bloomberg TV on Thursday. "You cannot make a return on investment if you don't have access to the U.S. market," Bancel told Bloomberg TV on the sidelines of the World Economic Forum in Davos. Bancel said regulatory delays and little support from the authorities make the market size "much smaller."

Read more of this story at Slashdot.

An anonymous reader quotes a report from the New York Times: Weight-loss drugs like Ozempic have transformed millions of lives with easily administered treatments and quick results. Now it turns out the dropped pounds may have a surprising perk for airlines, too: lower fuel costs, as slimmer passengers lighten their aircraft's loads. According to a study published last week by Jefferies, a financial services firm, the four largest U.S. carriers -- American Airlines, Delta Air Lines, Southwest Airlines and United Airlines -- could together save as much as $580 million per year on fuel thanks to weight-loss drugs, known as GLP-1s. One in eight U.S. adults said they were taking a GLP-1 in a November survey published by KFF, a nonprofit health research group. Fuel is among airlines' largest expenses. The Jefferies study estimates that the four airlines will together consume 16 billion gallons of fuel in 2026 at a total cost of $38.6 billion, nearly 20 percent of their total expenses. The savings from skinnier passengers would amount to just 1.5 percent of fuel costs. But airlines and pilots must scrutinize even the smallest changes to a plane's weight and balance, and a lighter payload means each jet burns less fuel to generate the thrust necessary to fly. Investors could also stand to benefit: The researchers estimated that a 2 percent reduction in aircraft weight could boost earnings per share by about 4 percent. "Please note savings are before any lost snack sales," the Jefferies analysts added.

Read more of this story at Slashdot.

Many people who stop using weight loss drugs will return to their previous weight within two years, a new review of existing research has found. CNN adds: This rate of weight regain is significantly faster than that seen in those who have lost weight by changing other lifestyle factors, such as diet and exercise, rather than relying on GLP-1 medications, researchers from the University of Oxford report in a paper published Wednesday in The BMJ journal. GLP-1, which stands for glucagon-like peptide-1, is a hormone naturally made by the body that helps signal to the brain and the gut that it's full and doesn't need to eat any more. Weight loss drugs mimic the action of this hormone by increasing the secretion of insulin to lower blood sugar. They also slow the movement of food through the digestive tract, which helps people feel full more quickly and for longer, and they work in the brain to reduce appetite.

Read more of this story at Slashdot.

An anonymous reader quotes a report from DealBook: Fifteen years ago, Daniel Ek broke into America's digital-content wars with his streaming music start-up, Spotify, which has turned into a publicly traded company with a $110 billion market value. Now he and his business partner, the Swedish entrepreneur Hjalmar Nilsonne, aim to crack a higher-stakes consumer market: American health care. The pair plan to bring Neko Health, the health tech start-up they founded in 2018, to New York this spring, DealBook is first to report. Mr. Ek and Mr. Nilsonne hope to capitalize on the growing number of prevention-minded Americans who are hungry to track their biometric data. Whether through wearables like Oura rings or more intensive screenings, consumers are turning to technology to improve their health and help spot the early onset of some big killers, including cardiovascular and metabolic diseases. The United States will be the third market, after Sweden and Britain, for Neko Health, which offers full-body diagnostic scans and is valued at roughly $1.7 billion. [...] Mr. Nilsonne and Mr. Ek said Neko Health's big aim was to change the health care model, in which spending across much of the developed world skyrockets but longevity gains have stalled. They want to make their noninvasive scans as routine as an annual checkup. The company, which advertises its service as "a health check for your future self," did not say what the U.S. scans would cost. But in Stockholm, an hourlong visit at one of its clinics costs 2,750 Swedish krona (about $300). Prenuvo's and Ezra's most comprehensive scans can cost $3,999. [...] Neko Health's technology differs from that of many of its U.S. rivals. It does not use M.R.I. or X-rays, instead relying on scores of sensors and cameras and a mix of proprietary and off-the-shelf technologies to measure heart function and circulation, and to photograph and map every inch of a patient's body looking for cancerous lesions. At the moment, the company's biggest challenge is scaling. [...] Mr. Nilsonne said Neko Health scans have detected the early onset of diseases or serious medical conditions for thousands of its patients. But the medical community is divided on the need for proactive screening technologies. The fear is that mass adoption could spur a wave of false positives and send healthy people to seek follow-up medical advice, overwhelming an already swamped health care system. Mr. Ek and Mr. Nilsonne believe they have built a better solution. And now they're ready to test it in the U.S. market.

Read more of this story at Slashdot.

Doctors say they have achieved the previously impossible -- restoring sight and preventing blindness in people with a rare but dangerous eye conditon called hypotony. From a report: Moorfields hospital in London is the world's first dedicated clinic for the disorder and seven out of eight patients given the pioneering treatment have responded to the therapy, a pilot study shows. One of them -- the first-ever -- is Nicki Guy, 47, who is sharing her story exclusively with the BBC. She says the results are incredible: "It's life-changing. It's given me everything back. I can see my child grow up. "I've gone from counting fingers and everything being really blurry to being able to see." Currently, she can see and read most lines of letters on an eye test chart. She is one line away from what is legally required for driving - a massive change from being partially sighted, using a magnifying glass for anything close up and having to navigate around the house and outside largely using memory. "If my vision stays like this for the rest of my life it would be absolutely brilliant. I may not ever be able to drive again but I'll take that!" she says. With hypotony, pressure within the eyeball becomes dangerously low, leading it to cave in on itself.

Read more of this story at Slashdot.

Microbiology had its golden age in the late nineteenth century, when researchers identified the bacterial causes of tuberculosis, cholera, typhoid, and a dozen other diseases in rapid succession. Antibiotics had theirs in the mid-twentieth century. Both booms eventually slowed. Vaccine development, by contrast, appears to be speeding up -- and the most productive era may still lie ahead, Works in Progress writes in a story. In the first half of the 2020s alone, researchers delivered the first effective vaccines against four different diseases: Covid-19, malaria, RSV and chikungunya. No previous decade matched that output. The acceleration rests on infrastructure that took two centuries to assemble. Edward Jenner's 1796 smallpox vaccine was a lucky accident he didn't understand. Louis Pasteur needed ninety years to turn that luck into systematic methods -- attenuation and inactivation -- that could be applied to other diseases. Generations of scientists then built the supporting machinery: Petri dishes for bacterial culture, techniques to keep animal cells alive outside the body, bioreactors for industrial production, sterilization and cold-chain logistics. Those tools have now compounded. Cryo-electron microscopy reveals viral proteins atom by atom, a capability that directly enabled the RSV vaccine after earlier attempts failed. Genome sequencing costs collapsed from roughly $100 million per human genome in 2001 to under $1,000 by 2014, according to data from the National Human Genome Research Institute. The mRNA platform, refined through work by Katalin Kariko, Drew Weissman, and others, allows vaccines to be redesigned in weeks rather than years. The trajectory suggests more breakthroughs are possible. Whether they arrive depends on continued investment, however.

Read more of this story at Slashdot.